Unveiling WHIM syndrome: Mavorixafor’s emerging role in immune restoration and therapy
Clinical and Experimental Immunology · 21.01.2025 · 219 (1)
DOI: 10.1093/cei/uxaf014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 11.03.2025. Verfasst von Muhammad Sohaib Khan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, DOW University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Warts, Receptors, CXCR4, Primary Immunodeficiency Diseases, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
WHIM syndrome is a rare autosomal dominant immunodeficiency disorder and is an abbreviation formed from the initial letters of its main clinical presentations: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. It stems mainly from mutations where there is a gain of function in the chemokine receptor CXCR4, which is extensively located on leukocytes and significantly affects the balance of the immune system. Many therapeutic strategies have been widely explored for several years for this immunodeficiency disorder. Mavorixafor, a CXCR4 antagonist, is a recently approved drug by the Food and Drug Administration (FDA) that is being studied for its longer half-life and oral drug route against WHIM syndrome. This review aims to investigate briefly the underlying mechanisms and pathogenesis of WHIM syndrome, and the current effective treatment approaches, for example CXCR4 antagonists or Hematopoietic Stem Cell Transplantation (HSCT), against it. The review also aims to thoroughly assess the efficacy and safety of Mavorixafor in managing WHIM syndrome, exploring its pharmacokinetics, pharmacodynamics, dosing regimens, and safety. Finally, we also investigate important additional therapeutic uses of Mavorixafor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, DOW University of Health Sciences, Karachi, Pakistan.
- Department of Internal Medicine, Avicenna Medical College, Lahore, Pakistan.
- Department of Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
- Department of Internal Medicine, Federal Medical and Dental College, Islamabad, Pakistan.
- Department of Internal Medicine, Ziauddin University, Karachi, Pakistan.
- Hitec-Ims, Taxila, Pakistan.
ORCID-Profile: Muhammad Sohaib Khan, Aqsa Kabir
Zitieren
APA
Khan, M. S., Azeem, B., Kanwal, A., Ahmed, I. E., Zehra, A., Kabir, A., Ahmed, W., Nasir, H., Khan, M., Manzoor, A., Hasanain, M., Moeen, W., Khan, M., & Ahmed, G. (2025). Unveiling WHIM syndrome: Mavorixafor’s emerging role in immune restoration and therapy. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxaf014
Vancouver
Khan MS, Azeem B, Kanwal A, Ahmed IE, Zehra A, Kabir A, et al. Unveiling WHIM syndrome: Mavorixafor’s emerging role in immune restoration and therapy. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxaf014
BibTeX
@article{Khan2025,
author = {Khan, Muhammad Sohaib and Azeem, Bismah and Kanwal, Ashir and Ahmed, Ifra Eeman and Zehra, Anum and Kabir, Aqsa and Ahmed, Waleed and Nasir, Hania and Khan, Momina and Manzoor, Aatika and Hasanain, Muhammad and Moeen, Wania and Khan, Muzamil and Ahmed, Gulrayz},
title = {Unveiling WHIM syndrome: Mavorixafor’s emerging role in immune restoration and therapy},
journal = {Clinical and Experimental Immunology},
year = {2025},
volume = {219},
number = {1},
doi = {10.1093/cei/uxaf014}
}
EUVIMED